电邮这篇文章 患者重建手术后下肢重症缺血的血栓形成并发症的现代预防方法的优势
- 作者: Katelnitskiy I.I.1, Katelnitskiy I.I.1, Livadnyaya E.S.1
-
隶属关系:
- Rostov State Medical University
- 期: 卷 27, 编号 4 (2019)
- 页面: 487-494
- 栏目: Original study
- URL: https://journals.rcsi.science/pavlovj/article/view/11798
- DOI: https://doi.org/10.23888/PAVLOVJ2019274487-494
- ID: 11798
如何引用文章
详细
目的：根据凝血数据和T-2血栓动力学测试结果，基于血栓形成危险因素诊断的改善，减少血栓形成并发症的发生概率之后来评估和改善下肢缺血严重的闭塞性动脉粥样硬化患者的再建手术水平。
材料与方法：给第一组的患者（n=48）进行了下肢动脉重建手术，并用于抗凝治疗（ACT）与未分馏肝素（UFH）是手术治疗前及手术6个小时和6天后的止血检查的控制下进行，以及在引入核苷三磷酸（NTP）30分钟前额外控制活化部分凝血活酶时间（APTT）的进行。给第二组的患者（n=34）进行了重建手术，用于抗凝治疗（ACT）使用止血检查的指标和实验室诊断系统《血栓形成动力学测试T-2的记录仪》手术治疗前及手术6个小时和6天，以及在引入普通肝素（UH）30分钟前额外控制活化部分凝血活酶时间（APTT）的进行。
结果：在分析凝血时间图和T-2血栓动力学测的结合数据时，APTT、纤维蛋白原、血凝块生长延迟时间、初始血凝块生长速率显示统计学意义，其中的组合提供了合理的机会来确定需要调整肝素治疗以防止血栓形成。
讨论：在选择肝素剂量的过程中T-2血栓动力学测的指标动态确认该方法在选择适当剂量的未分馏肝素为预防手术后血栓形成方面下肢缺血患者的巨大效力。
作者简介
Ivan Katelnitskiy
Rostov State Medical University
Email: katelnizkji@mail.ru
ORCID iD: 0000-0001-9913-740X
SPIN 代码: 1301-6207
Researcher ID: P-5936-2016
MD, PhD, Professor, Head of the Department of Surgical Diseases №1
俄罗斯联邦, Rostov-on-DonIgor Katelnitskiy
Rostov State Medical University
Email: katelnizkji@mail.ru
ORCID iD: 0000-0002-3745-9064
SPIN 代码: 3583-6234
Researcher ID: P-4046-2016
MD, PhD, Associate Professor, Professor of the Department of Surgical Diseases №1
Ekaterina Livadnyaya
Rostov State Medical University
编辑信件的主要联系方式.
Email: livadnyaya@mail.ru
ORCID iD: 0000-0002-1148-1044
SPIN 代码: 2252-5492
Researcher ID: G-9409-2019
MD, PhD, Assistant of the Department of Surgical Diseases №1
俄罗斯联邦, Rostov-on-Don参考
- Casu B, Naggi A, Torri G. Re-visiting the structure of heparin. Carbohydrate Research. 2015;403:60-8. doi: 10.1016/j.carres.2014.06.023
- Pityk OI, Prasol VA, Boĭko VV. The choice of the revascularization method in the patients with critical ischemia of the lower extremities. Klinichna Khirurhiia. 2013;(4):48-51.
- Abramov IS, Maitesyan DA, Lazaryan TA, et al. Remote results of semiclosed endarterectomy with a loop from the superficial femoral artery and femoropopliteal bypass grafting. Angiology and Vascular Surgery. 2014;20(4):147-51. (In Russ).
- Bajwa A, Wesolowski R, Patel A, et al. Assessment of Tissue Perfusion in the Lower Limb: Current Methods and Techniques Under Development. Circulation: Cardiovascular Imaging. 2014;7(5):836-43. doi: 10.1161/circimaging.114.002123
- Kovalenko VI, Temrezov MB, Klimovich LG, et al. Risk factors for thrombotic events in patients with critical lower extremity ischemia. Russian Medical Journal. 2012;(1):34-7. (In Russ).
- Clagett GP, Sobel M, Jackson MR, et al. Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl): 609S-26S. doi: 10.1378/chest. 126.3_suppl.609S
- Neufang A, Dorweiler B, Espinola-Klein C, et al. Outcomes of complex femorodistal sequential autologous vein and biologic prosthesis composite bypass grafts. Journal of Vascular Surgery. 2014; 60(6):1543-53. doi: 10.1016/j.jvs.2014.07.103
- Socea B, Constantin V, Carap A, et al. Lower limb revascularization – a continuous challenge. Chirurgia (Bucharest, Romania: 1990). 2011; 106(5):627-30.
- Bedenis R, Lethaby A, Maxwell H, et al. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database of Systematic Reviews. 2015;(2):CD000535. doi:10.1002/ 14651858.CD000535.pub3
补充文件
